Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.
Saved in:
| Title: | Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study. |
|---|---|
| Authors: | Urbanska EM; Department of Oncology, Center for Cancer and Organ Diseases, Righospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Institute for Clinical Medicine, University of Copenhagen UCPH, Copenhagen, Denmark., Grauslund M; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Sørensen JB; Department of Oncology, Center for Cancer and Organ Diseases, Righospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Institute for Clinical Medicine, University of Copenhagen UCPH, Copenhagen, Denmark. |
| Source: | Journal of thoracic disease [J Thorac Dis] 2026 May 31; Vol. 18 (5), pp. 559. Date of Electronic Publication: 2026 May 27. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 101533916 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2072-1439 (Print) Linking ISSN: 20721439 NLM ISO Abbreviation: J Thorac Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2072-1439 |
|---|---|
| DOI: | 10.21037/jtd-2026-1-0485 |
